As the FDA moves to speed early-stage clinical trials, former commissioners split on whether the public will see a reform or ...
Third positive data readout for the extended-release minoxidil positions drug for filing in male pattern hair loss, with ...
AdvaMed CEO Scott Whitaker listed tariffs, user fees, reimbursement predictability and strengthening cybersecurity as his top ...
Office of Dietary Supplement Programs announces availability of “New Dietary Ingredient (NDI) Notifications and Related ...
What's happening, why it matters and what's next at FDA. This edition explores the agency's approval of Alcon's Brytly ...
Dr. Squatch’s proposed $9m settlement over ‘natural’ claims and Sol de Janeiro’s trade dress dispute with MCoBeauty offer two ...
Chief global commercialization officer Anthony Mancini talked to Scrip about why the company is building a commercial ...
Proposals for a regulatory sandbox system in Brazil were informed by experiences in other countries, and a pilot involving ...
Fractyl’s Revita met the six-month co-primary endpoint in the 308-patient REMAIN-1 pivotal study, and a De Novo request is ...
Medicines For Europe has suggested that the Netherlands’ proposal to transpose the Urban Waste Water Treatment Directive ...
The UK agency confirms an AI center, early access scheme and PCCPs in a push for more adaptive regulation – but industry ...
Richard Forshee said on LinkedIn that he has returned to CBER as director of the Office of Biostatistics and Pharmacovigilance, the office he was running when former CBER Director Vinay Prasad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results